Mesh.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Mesh.i » - entrée « Interleukin-6 »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Interleukin-5 Receptor alpha Subunit < Interleukin-6 < Interleukin-6 Receptor alpha Subunit  Facettes :

List of bibliographic references indexed by Interleukin-6

Number of relevant bibliographic references: 487.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000011 (2020) Binqing Fu ; Xiaoling Xu ; Haiming WeiWhy tocilizumab could be an effective treatment for severe COVID-19?
000197 (2020) Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
000318 (2020) Peter Uciechowski [Allemagne] ; Wolfram C M. Dempke [Allemagne]Interleukin-6: A Masterplayer in the Cytokine Network.
000350 (2020) Anna-Sophia Kattner ; Ernst Holler ; Barbara Holler ; Sebastian Klobuch ; Daniela Weber ; Danilo Martinovic ; Matthias Edinger ; Wolfgang Herr ; Daniel WolffIL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis
000351 (2020) Etienne Dufranc [France] ; Arnaud Del Bello [France] ; Julie Belliere [France] ; Nassim Kamar [France] ; Stanislas Faguer [France]IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
000355 (2020) Heidi LedfordHow does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
000381 (2020) Xuhan Zhang [République populaire de Chine] ; Kaidi Song [République populaire de Chine] ; Fei Tong [République populaire de Chine] ; Mingming Fei [République populaire de Chine] ; Hui Guo [République populaire de Chine] ; Zhaohui Lu [République populaire de Chine] ; Jinquan Wang [République populaire de Chine] ; Changcheng Zheng [République populaire de Chine]First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
000415 (2020) Tomoyuki Asano ; Shuzo Sato ; Jumpei Temmoku ; Yuya Fujita ; Makiko Yashiro Furuya ; Naoki Matsuoka ; Hiroko Kobayashi ; Eiji Suzuki [Japon] ; Hiroshi Watanabe ; Kiyoshi MigitaEffectiveness of Tocilizumab in juvenile patients with refractory Takayasu arteritis
000494 (2020) Naoto Sakumura [Japon] ; Hitoshi Irabu [Japon] ; Natsumi Inoue [Japon] ; Mao Mizuta [Japon] ; Masaki Shimizu [Japon]Clinical usefulness of longitudinal IL-6 monitoring in a patient with Takayasu aortitis receiving tocilizumab.
000700 (2019) Martin Krusche [Allemagne] ; Nikolas Ruffer [Allemagne] ; Ina Kötter [Allemagne]Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature.
000704 (2019) Kentaro Chino [Japon] ; Tsuneo Kondo [Japon] ; Ryota Sakai [Japon] ; Shuntaro Saito [Japon] ; Yusuke Okada [Japon] ; Akiko Shibata [Japon] ; Takahiko Kurasawa [Japon] ; Ayumi Okuyama [Japon] ; Hirofumi Takei [Japon] ; Koichi Amano [Japon]Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single-center, open-label study.
000719 (2019) Kazutoshi Ebisawa [Japon] ; Yosuke Masamoto [Japon] ; Junji Tokushige [Japon] ; Hiroshi Nishi [Japon] ; Kenjiro Honda [Japon] ; Munetoshi Hinata [Japon] ; Kazuhiro Toyama [Japon] ; Masaomi Nangaku [Japon] ; Mineo Kurokawa [Japon]Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
000739 (2019) Niklas Prenissl [Allemagne] ; Juliane Lokau [Allemagne] ; Stefan Rose-John [Allemagne] ; Johannes Haybaeck [Autriche] ; Christoph Garbers [Allemagne]Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.
000767 (2019) Yoshihito Shima [Japon]The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis.
000794 (2019) In-Hye Ham [Corée du Sud] ; Hye Jeong Oh [Corée du Sud] ; Hyejin Jin [Corée du Sud] ; Cheong A. Bae [Corée du Sud] ; Sang-Min Jeon [Corée du Sud] ; Kyeong Sook Choi [Corée du Sud] ; Sang-Yong Son [Corée du Sud] ; Sang-Uk Han [Corée du Sud] ; Rolf A. Brekken [États-Unis] ; Dakeun Lee [Corée du Sud] ; Hoon Hur [Corée du Sud]Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer.
000855 (2019) Christoph T. Berger [Suisse] ; Birke Rebholz-Chaves [Suisse] ; Mike Recher [Suisse] ; Tobias Manigold [Suisse] ; Thomas Daikeler [Suisse]Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses.
000889 (2019) Ryuhei Yasuoka [Japon] ; Naomi Iwata [Japon] ; Naoki Abe [Japon] ; Toaki Kohagura [Japon] ; Haruna Nakaseko [Japon] ; Masaki Shimizu [Japon] ; Shinji Kawabe [Japon]Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
000984 (2019) Florian Kleinegger [Autriche] ; Eva Hofer [Autriche] ; Christina Wodlej [Autriche] ; Nicole Golob-Schwarzl [Autriche] ; Anna Maria Birkl-Toeglhofer [Autriche] ; Alexander Stallinger [Autriche] ; Johannes Petzold [Autriche] ; Anna Orlova [Autriche] ; Stefanie Krassnig [Autriche] ; Robert Reihs [Autriche] ; Tobias Niedrist [Autriche] ; Harald Mangge [Autriche] ; Young Nyun Park [Corée du Sud] ; Michael Thalhammer [Autriche] ; Ariane Aigelsreiter [Autriche] ; Sigurd Lax [Autriche] ; Christoph Garbers [Allemagne] ; Peter Fickert [Autriche] ; Stefan Rose-John [Allemagne] ; Richard Moriggl [Autriche] ; Beate Rinner [Autriche] ; Johannes Haybaeck [Allemagne]Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
000A01 (2019) Hajime Yoshifuji [Japon]Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
000A64 (2019) Masayoshi Harigai [Japon] ; Michi Tsutsumino [Japon] ; Hideto Takada [Japon] ; Kenji Nagasaka [Japon]Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis.
000B00 (2019) Yueh-Shan Weng [Taïwan] ; Hong-Yu Tseng [Taïwan] ; Yen-An Chen [Taïwan] ; Pei-Chun Shen [Taïwan] ; Aushia Tanzih Al Haq [Taïwan] ; Li-Mei Chen [Taïwan] ; Yi-Chung Tung [Taïwan] ; Hsin-Ling Hsu [Taïwan]MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Interleukin-6" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Interleukin-6" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Interleukin-6
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021